Bio-Rad Laboratories Underperforms Amidst Disappointing Results and Industry Headwinds.
ByAinvest
Friday, Mar 20, 2026 8:14 am ET1min read
AVTR--
Longleaf Partners Global Fund highlighted Bio-Rad Laboratories as a disappointing investment in 2025 due to poor results and government spending cutbacks. However, the company showed operational improvement and is expected to grow its free cash flow in 2026. Despite this, the fund chose to exit its position in Avantor, another life-sciences company, after a leadership change and guidance reset. The fund returned 5.27% in Q4 2025, compared to the MSCI World's 3.12% and MSCI World Value's 3.34% return.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet